+
Cards In This Set
| Front | Back |
|
How do you define scleroderma?
|
Limited: distal to elbows and kneessystemic proximal to elbows and kneesnote: face can be involved in both
|
|
What is uncommon AE of infliximab?
|
Drug-induced SLE
|
|
What is biologic of first choice for RA?
|
Etanercept
|
|
Is psoriasis occurs explosively in a pt, what should you think of?
|
HIV
|
|
How does drug-induced lupus differ in terms of clinical px?
|
Fever, arthralgia, and serositis (more pleuropericardial disease and cutaneous findings- circular plaques on neck, trunk and extensor surfaces of arms), always antihistone +; and renal and neuro involvement is rare
|
|
How should aggressive RA be treated?
|
Start biologic; if one fails, switch to another because patients who don't respond to one may respond to another (infliximab, or adalimumab
|
|
How is scleroderma treated?
|
Only treat symptoms (e.g. PPI for GERD)for lung involvement, cyclophosphamide shown to be effectiveAVOID STEROIDS - not effective and can precipitate renal crisis
|
|
What triad is diagnostic of knee OA?
|
Age > 50, no warmth, morning stiffness < 30 min, crepitus, bony enlargement, bony tenderness
|
|
How is lupus nephritis treated?
|
Remission therapy: cyclophosphamide q month for 3-6 monthsMaintenance phase: mycophenolate mofetil, or azathrioprine; alternative: cyclophosphamide q 3 months for up to 18 months
|
|
How do you distinguish APL antibody syndrome from a SLE flare, since both can have neuro and renal complications?
|
APL: no hypocomplementemia, or inflammatory markers (ESR
|
|
If you have a high suspicion for lupus nephritis, should you wait for biopsy before treating?
|
NO!
|
|
What are studies of choice in a pt who you think may have SLE?
|
ANA, ESR, CBC, and U/A
|
|
What biologics cause SLE?
|
TNF alpha blockers, interferon alpha, and IL-2
|
|
What are common (classic) drug induced SLE causes?
|
Procainamide, quinidine, methyldopa, hydralazine, isoniazid, minocycline
|
|
What are best drugs for early, nonerosive RA?
|
Sulfasalazine or plaquenil
|
